Top

Published in:

01-10-2009 | Case Report

Amiodarone for Pediatric Resuscitation: A Word of Caution

Authors: Steven B. Fishberger, Robert L. Hannan, Elizabeth M. Welch, Anthony F. Rossi

Published in: Pediatric Cardiology | Issue 7/2009

Abstract

Intravenous administration of amiodarone has recently been recommended for use during pediatric resuscitation of pediatric patients with ventricular fibrillation or pulseless ventricular tachycardia. We present two pediatric patients who received amiodarone for polymorphic ventricular tachycardia, although they were ultimately determined to have congenital long QT syndrome. Amiodarone is contraindicated in this setting and may have exacerbated the ventricular arrhythmia.

American Heart Association (2005) American Heart Association 2005 guidelines for cardiopulmonary resuscitation and emergency cardiovascular care of pediatric and neonatal patients: Pediatric basic life support. Circulation 112:IV1–203

Bar-Cohen Y, Silka MJ (2006) Congenital long QT syndrome: diagnosis and management in pediatric patients. Curr Treat Options Cardiovasc Med 8:387–395PubMedCrossRef

Figa FH, Gow RM, Hamilton RM, Freedom RM (1994) Clinical efficacy and safety of intravenous Amiodarone in infants and children. Am J Cardiol 74:573–577PubMedCrossRef

Haas NA, Camphausen CK (2008) Impact of early and standardized treatment with amiodarone on therapeutic success and outcome in pediatric patients with postoperative tachyarrhythmia. J Thorac Cardiovasc Surg 136:1215–1222PubMedCrossRef

International Liaison Committee on Resuscitation (2005) International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Part 6: Pediatric basic and advanced life support. Resuscitation 67:271–291CrossRef

Nkomo VT, Shen WK (2001) Amiodarone-induced long QT and polymorphic ventricular tachycardia. Am J Emerg Med 19:246–248PubMedCrossRef

Perry JC, Fenrich AL, Hulse JE, Triedman JK, Friedman RA, Lamberti JJ (1996) Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol. J Am Coll Cardiol 27:1246–1250PubMedCrossRef

Plumpton K, Justo R, Hass N (2005) Amiodarone for post-operative junctional ectopic tachycardia. Cardiol Young 15:13–18PubMedCrossRef

Saul JP, Scott WA, Brown S et al (2005) Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation 112:3470–3477PubMedCrossRef

10.

Yabek SM (2007) Preventing pediatric sudden cardiac death. Pediatrics 119:407–408PubMedCrossRef

Title: Amiodarone for Pediatric Resuscitation: A Word of Caution
Authors: Steven B. Fishberger
Robert L. Hannan
Elizabeth M. Welch
Anthony F. Rossi
Publication date: 01-10-2009
Publisher: Springer-Verlag
Published in: Pediatric Cardiology / Issue 7/2009
Print ISSN: 0172-0643
Electronic ISSN: 1432-1971
DOI: https://doi.org/10.1007/s00246-009-9470-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

Amiodarone for Pediatric Resuscitation: A Word of Caution

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2009

Case Report by Awad and Coworkers

A Difficult Emergency Surgical Diagnosis: Atresia of the Common Pulmonary Vein

Upcoming Events in Pediatric Cardiology

Preclosure Pressure Gradients Predict Patent Ductus Arteriosus Patients at Risk for Later Left Pulmonary Artery Stenosis

Right Ventricular Subclinical Diastolic Dysfunction in Obese Children: The Effect of Weight Reduction with a Low-Carbohydrate Diet

PTPN11 Gene Mutation and Severe Neonatal Hypertrophic Cardiomyopathy: What Is the Link?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page